Atai Beckley N.V (ATAI) Stock

Atai Beckley N.V (ATAI) is a Healthcare stock trading at $4.05 (as of 2026-06-18), with a market capitalization of $1.67B and a trailing P/E of -1.4. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Atai Beckley N.V. is a clinical-stage biopharmaceutical company focused on treating mental health disorders. The company was founded in June 2018 by Christian Angermayer, Florian Brand, Srinivas Rao, and Lars Christian Wilde, and is headquartered in Amstelveen, Netherlands.

Valuation — source: SEC EDGAR (first-party)
Price	$4.05
Market Cap	$1.67B
P/E Ratio	-1.4
EV / EBITDA	-2.4
Price / Book	7.26
Price / Sales	413.77
DCF Value (model)	$-4.97
DCF Upside vs Price	-222.7%

Profitability & Growth — source: SEC EDGAR
Revenue (TTM)	$4.09M
Net Margin	-16142.0%
Return on Equity	-333.7%
Debt / Equity	0.84
Current Ratio	10.02
Revenue Growth (YoY)	-38.6%
EPS Growth (YoY)	-46.7%
FCF Growth (YoY)	16.5%

Financial Health — source: SEC EDGAR
Altman Z-Score	-0.19 (distress)

Valuation vs Sector & Industry
Stock P/E	-1.4
Sector P/E (Healthcare)	21.0
Industry P/E (Pharmaceutical Products)	17.3
vs Sector	-106.6%
vs Industry	-108.0%

Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional Holder	Deep Track Capital, LP ($42.48M)
Institutional Holders Tracked	10

Company
Sector	Healthcare
Industry	Pharmaceutical Products
CEO	Srinivas G. Rao
Employees	54
Country	NL
IPO Date	2021-06-18

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

Data as of 2026-06-18.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.